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Geographical variations in healthcare utilisation can 
perpetuate health disparities.[1] Use of preventive 
services is particularly likely to be low when access 
to health services is a barrier.[2-5] In addition, there is a 
strong association between a population’s residential 
location or region and use of preventive screening services.[6-8] 
As a result, there are wide variations in healthcare utilisation 
and health outcomes across the provinces of South Africa (SA).[9] 
Gauteng and the Western Cape are economically more prosperous 
and urbanised, are better resourced, and have superior health and 
development indicators compared with poorer provinces such as 
Limpopo and the Northern Cape.[10] Access to medical insurance 
is positively associated with the use of preventive care services.
[11,12] Approximately 14% of SA’s population currently has access to 
medical insurance.[13] Little is known about provincial disparities in 
healthcare utilisation in the privately insured sector, or what factors 
drive these disparities.
Discovery Health, the largest medical aid in SA, with an 
approximately 40% market share, offers a fully paid screening 
programme for its members. This study aimed to investigate the 
variation in use of preventive screening services of the Discovery 
Health membership across the nine provinces of SA. Given that 
all members have equal access to preventive services, other factors 
may be at play if disparities do exist. Understanding the provincial 
disparities may steer more targeted messaging or further research 
into defining reasons, such as health and human resources availability 
and capacity, for varying preventive care use.
Materials and methods
Setting
The study population consisted of all members of Discovery Health 
medical aid as at the end of 2011. The Discovery Health screening 
programme offers a paid screening benefit to its members for 
mammograms, Pap smears, HIV tests, glaucoma screening, prostate-
specific antigen (PSA) for prostate cancer screening, random glucose and 
cholesterol tests, ’flu vaccines and pneumococcal vaccines, irrespective of 
the type of medical plan members belong to. Other preventive screening 
tests are not fully paid for and have some form of co-payments; these 
include colorectal cancer and osteoporosis screening. The Human 
Research Ethics Committee of the University of the Witwatersrand 
granted ethical clearance for the study (certificate No. M120854).
Methods
Eligibility criteria for the tests evaluated were adapted from the US 
Preventive Services Task Force Recommendations and are outlined 
in Table 1. Some preventive tests have clear recommendations for 
screening frequency, while others do not. For this study, screening for 
a disease was characterised as having had at least one of the screening 
tests outlined in Table 1 for the calendar year of 2011 (annual 
average). It is therefore not an evaluation of whether members’ 
screening behaviour adheres to screening recommendations. The 
study also did not evaluate differences between covered and non-
covered tests, but simply the provincial variation in annual screening 
rates. Each member was assigned to one of the nine provinces 
according to a valid address in that province for the duration of 2011.
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Background. Screening for asymptomatic diseases can reduce the burden of morbidity and mortality in all population groups. There is 
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Objective. To examine screening rates for chronic diseases of lifestyle (CDL), HIV and cancer in a privately insured population for a single 
insurer across all nine provinces in South Africa, and to determine whether or not there are any differences between the provinces.
Method. Screening rates were calculated as the proportion of eligible members who had received screening tests during 2011 in each 
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Results. Nationwide screening rates were 20.5% for CDL, 8.2% for HIV and 31.9% for cancer. Despite similar insurance coverage, screening rates 
ranged from 0.3% to 0.95% lower in other provinces compared with Gauteng. Of all the provinces, Gauteng had the highest annual screening 
rates for CDL, breast cancer, prostate cancer and HIV (p<0.001), while the Western Cape had the highest rate for cervical cancer (p<0.001).
Conclusion. There is much variation in preventive care utilisation across the provinces within this health-insured population. Provinces 
with more abundant healthcare resources have higher screening rates. Further research is required to understand the reasons for the 
variation, given equal payment access.
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Statistical analyses
The study was a cross-sectional descriptive analysis of the annual 
screening rate of all eligible medical aid members in 2011 across all 
nine provinces. The mean screening rate for each test was compared 
between provinces using Student’s t-test for unpaired samples, with 
Gauteng as the baseline. Variation between provinces was described 
using ratios of differences. All analyses were conducted using STATA 
12.0 (StataCorp, USA).
Results
Screening rates for a total of 1 889 447 members were evaluated for 
the year 2011. Descriptive statistics of the study sample by province 
are reported in Table 2. The provincial screening rates are shown in 
Table 3.
Gauteng had the highest annual screening rate for cholesterol 
at 27.5% of eligible insured members, and the Northern Cape the 
lowest at 13.4%. Gauteng’s screening rate for cholesterol was also 
significantly higher than those of the other provinces, figures for 
which were between 0.93 (Western Cape) and 0.49 (Northern Cape) 
times lower than Gauteng (p<0.001). The variations in screening 
rates are shown in Table 4. The highest annual screening rate for 
glucose was 29.7% (Mpumalanga), although this was not significantly 
different from Gauteng’s 29.6% (p=0.97). The lowest screening rate 
for glucose was in the Northern Cape (17.5%), with a variation of 0.59 
times lower than Gauteng. KwaZulu-Natal had a 0.84 times lower 
screening for cholesterol than Gauteng.
Prostate cancer screening had the highest uptake of all preventive 
screening tests. Around 37.7% of males over 50 years old had had a 
PSA test in Gauteng, versus a low of 25.6% of males in the Northern 
Cape. Gauteng had the highest screening rate for prostate cancer of 
all the provinces (p<0.001), and screening rates for prostate cancer 
ranged from 0.90 to 0.68 times lower in other provinces compared 
with Gauteng.
The Western Cape had the highest cervical cancer screening rate 
(p<0.001), with 23.1% of all eligible females having had a Pap smear 
versus only 13.1% of females in the Northern Cape. The screening 
rate for cervical cancer in the Western Cape was 1.03 times higher 
than that in Gauteng, while the rate was 0.55 times lower in Limpopo 
than in Gauteng.
The highest screening rate for breast cancer was in Gauteng 
(p<0.001), with 17.0% of eligible females having had a mammogram, 
while the lowest rate of 9.4% was in the Northern Cape. Rates for 
mammograms ranged from 0.95 to 0.60 times lower in the other 
provinces compared with Gauteng.
HIV screening had the largest variation of all the screening tests. 
Gauteng had the highest rate (p<0.001), with 12.8% of members 
having had the test, and the lowest rate was in the Northern Cape, 
where only 4.8% of members had been tested in 2011. Northern Cape 
had a 0.38 times lower screening rate than Gauteng.
Colorectal cancer screening, currently not part of the paid 
screening benefit, had the lowest rate. The Eastern Cape (0.7%) 
had the highest rate (p<0.001), while the lowest rate (0.2%) was in 
Limpopo. The Eastern Cape’s screening rate was 1.17 times higher 
than Gauteng’s and 3.5 times higher than Limpopo’s.
Osteoporosis screening, which is also not part of the paid screening 
benefit, had the highest rate in Gauteng (p<0.001), with 7.9% of 
members undergoing screening, and the lowest rate in the Northern 
Cape (2.2%). Rates of screening for osteoporosis were between 0.82 
and 0.28 times lower in the other eight provinces than in Gauteng.
Screening rates for all the provinces are presented in Fig. 1, with 
Gauteng shown in black.
Table 1. Eligibility criteria for screening tests
Preventive care services Eligible population
Recommendations for how often tests should 
be performed
Cholesterol test 18 years and older Once every 5 years
Glucose test 18 years and older No well-established recommendation. Usually 
once every 5 years
Glaucoma screening 40 years and older No well-established recommendation
HIV 18 years and older No well-established recommendation. Usually 
yearly for persons at risk
Prostate cancer test Male, 50 years and older No well-established recommendation
Pap smear Female, 16 years and older Once every 3 years
Mammogram Female, 35 years and older Once every 2 years
Colorectal cancer screening 50 years and older Colonoscopy: once every 10 years
Sigmoidoscopy: once every 5 years
Faecal occult blood: yearly
Bone density scan Female, 50 years and older No well-established recommendation
Table 2. Descriptive statistics of the study sample by province
Province Frequency (n) %
Eastern Cape 98 211 5.20
Free State 50 415 2.76
Gauteng 895 202 47.38
KwaZulu-Natal 267 700 14.17
Limpopo 29 883 1.58
Mpumalanga 105 662 5.59
North West 55 787 2.95
Northern Cape 17 889 0.95
Western Cape 367 186 19.43
Non-RSA 1 509 0.08
Total 1 889 447 100
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Discussion
Use of screening services in this SA medical aid population is low 
and far below international benchmark targets of 93.0% for cervical 
cancer, 70.5% for colorectal cancer, 81.1% for breast cancer and 82.1% 
for cholesterol screening.[14] Surveys of screening rates in comparable 
populations showed that 68% of adults in the USA reported having 
had a cholesterol test in the preceding 5 years, and more than 
75% of females aged 40 years and older had had a mammogram 
in the preceding 2 years;[15] in European countries (Germany, the 
Netherlands, England and Italy), between 61% and 79% of females 
over 50 years were screened for breast cancer biennially. [15,16] Screening 
rates among medically insured individuals tend to be slightly higher 
than in the uninsured, with rates of up to 77.6% for mammograms, 
91.5% for Pap smears, 85.5% for cholesterol tests and 50.9% for 
colorectal cancer.[17]
There is considerable variation in utilisation of screening services 
between provinces in the SA insured population. Screening rates 
for chronic diseases of lifestyle varied from 30% to 50% lower in 
the Northern Cape and Limpopo compared with Gauteng and the 
Western Cape. Cancer screening ranged from 45% to 5% lower in 
some provinces compared with Gauteng. Rates of HIV screening 
in the Free State, North West and the Northern Cape were less than 
half that in Gauteng. This is consistent with findings of others that 
urbanised areas achieved better uptake of screening services.[18]
The variation in utilisation of screening services seen in this 
medically insured population may not be unusual. Even among 
medical aid members, where the costs of screening tests are paid 
for, and in settings where screening facilities are easily accessible, 
researchers have found poor uptake of services.[19,20] This confirms 
the previous conclusion that access alone is not the only driver of 
healthcare utilisation disparities.[1] Access to facilities may be better 
in the more urbanised provinces and may play a role in the unequal 
use of preventive services, together with several other individual and 
provider factors.[6,21] Further research is required to fully understand 
the reasons for inequitable use of preventive services across the nine 
provinces in this health insured population.
This study is limited by the fact that it focused only on annual 
uptake of screening services and not on adherence to screening 
guidelines, disease detection rates or treatment/management 
outcomes. Further research is necessary to analyse available data over 
longer time frames in order to establish the proportion of people 
who have availed themselves of recommended screening, as well 
Table 3. Provincial screening rates
  Cholesterol Glucose HIV Prostate Pap smear Mammogram Colorectal cancer Osteoporosis
National average*
(international targets – 
where they exist)†
20.5
(82.1)
23.8 8.2 31.9 16.7
(93.0)
13.3
(81.1)
0.4
(70.5)
5.7
Eastern Cape 21.9 23.8 7.3 33.8 17.5 12.1 0.7‡ 5.8
Free State 17.1 19.4 5.2 32.3 15.1 16.2 0.4 5.8
Gauteng 27.5‡ 29.6 12.8‡ 37.7‡ 22.4 17.0‡ 0.6 7.9‡
KwaZulu-Natal 23.2 26.3 10.2 27.2 16.9 13.2 0.3 4.9
Limpopo 19.7 20.7 11.0 29.4 12.3 9.4 0.2 6.0
Mpumalanga 18.6 29.7§ 6.7 32.6 15.1 12.6 0.3 6.5
North West 17.9 20.5 5.9 34.9 14.5 13.0 0.3 5.3
Northern Cape 13.4 17.5 4.8 25.6 13.1 10.2 0.4 2.2
Western Cape 25.5 26.6 9.9 33.8 23.1‡ 16.1 0.6 5.4
*Average proportion of eligible Discovery Health Members who utilise the screening service.
†Healthy People 2020 Targets (USA).14
‡Significant difference in screening rate when comparing Gauteng with other provinces/or compared with Gauteng (p<0.001).
§No significant difference in screening rate when compared with Gauteng (p=0.97).
Table 4. Variation in screening rates between Gauteng and the other provinces
Ratio by which province is lower (higher) than Gauteng
Province Cholesterol Glucose HIV Prostate Pap smear Mammogram Colorectal cancer Osteoporosis
Eastern Cape 0.78 0.80 0.57 0.90 0.78 0.71 (1.17) 0.73
Free State 0.62 0.66 0.41 0.86 0.67 0.95 0.67 0.73
KwaZulu-Natal 0.84 0.89 0.80 0.72 0.75 0.78 0.50 0.62
Limpopo 0.72 0.70 0.86 0.78 0.55 0.55 0.33 0.76
Mpumalanga 0.68 1.00 0.52 0.86 0.67 0.74 0.50 0.82
North West 0.65 0.69 0.46 0.78 0.65 0.76 0.50 0.67
Northern Cape 0.49 0.59 0.38 0.68 0.58 0.60 0.67 0.28
Western Cape 0.93 0.90 0.77 0.90 (1.03) 0.95 1.00 0.68
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as their health outcomes. Another limitation is that inferences in 
respect of screening rates can be drawn only on other groups within 
SA with similar health insurance coverage and not on the uninsured 
population. It is expected that the general uninsured population 
screening rate would be much lower than those of the health-insured 
population. Future research agendas should include comprehensive 
evaluation of all preventive screening services utilisation (CDL, 
cancers and HIV) in the uninsured population, with a view to 
establishing eligibility criteria and creating targets for utilisation 
of services at various national, provincial and district levels and 
strengthening national databases, given the imminent introduction 
of National Health Insurance. This study provides some indication 
of screening patterns at a national level and the variation that persists 
in this privately insured population. The strength of this study is 
that it analysed the entire health-insured population’s screening 
activity over a 1-year period at both national and provincial level 
and therefore accurately represents their annual screening practices 
compared with survey data estimations.
Conclusion
This is the first look at national screening practices in a South African 
population. In this health-insured population, screening varies 
greatly between provinces for CDL, cancers and HIV. Screening rates 
in the larger uninsured South African population may be even lower.
We found that the better-resourced provinces had higher 
screening rates. The variations between the provinces deserve further 
exploration in order to evaluate the effect of resource allocation, 
access to care, provider factors and socio-demographic characteristics 
that may impact on screening rates.
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Fig. 1. Provincial screening rates, 2011.
